<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:00:05Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4759630" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4759630</identifier><datestamp>2016-03-04</datestamp><setSpec>ncomms</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nat Commun</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Commun</journal-id>
      <journal-title-group>
        <journal-title>Nature Communications</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2041-1723</issn>
      <publisher>
        <publisher-name>Nature Publishing Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4759630</article-id>
      <article-id pub-id-type="pmcid">PMC4759630</article-id>
      <article-id pub-id-type="pmc-uid">4759630</article-id>
      <article-id pub-id-type="pmid">26888176</article-id>
      <article-id pub-id-type="pii">ncomms10713</article-id>
      <article-id pub-id-type="doi">10.1038/ncomms10713</article-id>
      <article-id pub-id-type="pmid">26888176</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Gomez-Ospina</surname>
            <given-names>Natalia</given-names>
          </name>
          <xref ref-type="aff" rid="a1">1</xref>
          <xref ref-type="author-notes" rid="n1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Potter</surname>
            <given-names>Carol J.</given-names>
          </name>
          <xref ref-type="aff" rid="a2">2</xref>
          <xref ref-type="author-notes" rid="n1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Xiao</surname>
            <given-names>Rui</given-names>
          </name>
          <xref ref-type="aff" rid="a3">3</xref>
          <xref ref-type="aff" rid="a4">4</xref>
          <xref ref-type="author-notes" rid="n1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Manickam</surname>
            <given-names>Kandamurugu</given-names>
          </name>
          <xref ref-type="aff" rid="a2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Mi-Sun</given-names>
          </name>
          <xref ref-type="aff" rid="a3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Kang Ho</given-names>
          </name>
          <xref ref-type="aff" rid="a3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shneider</surname>
            <given-names>Benjamin L.</given-names>
          </name>
          <xref ref-type="aff" rid="a5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Picarsic</surname>
            <given-names>Jennifer L.</given-names>
          </name>
          <xref ref-type="aff" rid="a6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jacobson</surname>
            <given-names>Theodora A.</given-names>
          </name>
          <xref ref-type="aff" rid="a2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Jing</given-names>
          </name>
          <xref ref-type="aff" rid="a4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>He</surname>
            <given-names>Weimin</given-names>
          </name>
          <xref ref-type="aff" rid="a4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Pengfei</given-names>
          </name>
          <xref ref-type="aff" rid="a4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Knisely</surname>
            <given-names>A. S.</given-names>
          </name>
          <xref ref-type="aff" rid="a7">7</xref>
          <xref ref-type="author-notes" rid="n2">â </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Finegold</surname>
            <given-names>Milton J.</given-names>
          </name>
          <xref ref-type="aff" rid="a8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Muzny</surname>
            <given-names>Donna M.</given-names>
          </name>
          <xref ref-type="aff" rid="a9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Boerwinkle</surname>
            <given-names>Eric</given-names>
          </name>
          <xref ref-type="aff" rid="a9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lupski</surname>
            <given-names>James R.</given-names>
          </name>
          <xref ref-type="aff" rid="a4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Plon</surname>
            <given-names>Sharon E.</given-names>
          </name>
          <xref ref-type="aff" rid="a4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gibbs</surname>
            <given-names>Richard A.</given-names>
          </name>
          <xref ref-type="aff" rid="a4">4</xref>
          <xref ref-type="aff" rid="a9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Eng</surname>
            <given-names>Christine M.</given-names>
          </name>
          <xref ref-type="aff" rid="a4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>Yaping</given-names>
          </name>
          <xref ref-type="aff" rid="a4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Washington</surname>
            <given-names>Gabriel C.</given-names>
          </name>
          <xref ref-type="aff" rid="a10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Porteus</surname>
            <given-names>Matthew H.</given-names>
          </name>
          <xref ref-type="aff" rid="a10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Berquist</surname>
            <given-names>William E.</given-names>
          </name>
          <xref ref-type="aff" rid="a11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kambham</surname>
            <given-names>Neeraja</given-names>
          </name>
          <xref ref-type="aff" rid="a12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Singh</surname>
            <given-names>Ravinder J.</given-names>
          </name>
          <xref ref-type="aff" rid="a13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Xia</surname>
            <given-names>Fan</given-names>
          </name>
          <xref ref-type="aff" rid="a4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Enns</surname>
            <given-names>Gregory M.</given-names>
          </name>
          <xref ref-type="aff" rid="a1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moore</surname>
            <given-names>David D.</given-names>
          </name>
          <xref ref-type="corresp" rid="c1">a</xref>
          <xref ref-type="aff" rid="a3">3</xref>
          <xref ref-type="aff" rid="a4">4</xref>
        </contrib>
        <aff id="a1"><label>1</label><institution>Lucile Packard Children's Hospital, Divisions of Medical Genetics, Stanford University Medical Center</institution>, Stanford, California 94305, <country>USA</country></aff>
        <aff id="a2"><label>2</label><institution>Section of Human and Molecular Genetics, Nationwide Children's Hospital</institution>, Columbus, Ohio 43205, <country>USA</country></aff>
        <aff id="a3"><label>3</label><institution>Department of Molecular and Cellular Biology, Baylor College of Medicine</institution>, Houston, Texas 77030, <country>USA</country></aff>
        <aff id="a4"><label>4</label><institution>Department of Molecular and Human Genetics, Baylor College of Medicine</institution>, Houston, Texas 77030, <country>USA</country></aff>
        <aff id="a5"><label>5</label><institution>Department of Pediatrics, Baylor College of Medicine</institution>, Houston, Texas 77030, <country>USA</country></aff>
        <aff id="a6"><label>6</label><institution>Department of Pathology, University of Pittsburgh School of Medicine</institution>, Pittsburgh, Pennsylvania 15261, <country>USA</country></aff>
        <aff id="a7"><label>7</label><institution>Institute of Liver Studies, King's College Hospital</institution>, London SE5 9R5, <country>UK</country></aff>
        <aff id="a8"><label>8</label><institution>Department of Pathology and Immunology, Baylor College of Medicine</institution>, Houston, Texas 77030, <country>USA</country></aff>
        <aff id="a9"><label>9</label><institution>Human Genome Sequencing Center, Baylor College of Medicine</institution>, Houston, Texas 77030, <country>USA</country></aff>
        <aff id="a10"><label>10</label><institution>Pediatric Stem Cell Transplantation, Stanford University Medical Center</institution>, Stanford, California 94305, <country>USA</country></aff>
        <aff id="a11"><label>11</label><institution>Pediatric Gastroenterology, Stanford University Medical Center</institution>, Stanford, California 94305, <country>USA</country></aff>
        <aff id="a12"><label>12</label><institution>Anatomic and Clinical Pathology, Stanford University Medical Center</institution>, Stanford, California 94305, <country>USA</country></aff>
        <aff id="a13"><label>13</label><institution>Immunochemistry Core Laboratory, College of Medicine, Mayo Clinic</institution>, Rochester, Minnesota 55902, <country>USA</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1">
          <label>a</label>
          <email>moore@bcm.tmc.edu</email>
        </corresp>
        <fn id="n1">
          <label>*</label>
          <p>These authors contributed equally to this work.</p>
        </fn>
        <fn id="n2">
          <label>â </label>
          <p>Present address: Institut fur Pathologie, Medizinishce Universitat Graz, A-803 Graz, Austria.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>02</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>7</volume>
      <elocation-id>10713</elocation-id>
      <history>
        <date date-type="received">
          <day>07</day>
          <month>07</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>01</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright Â© 2016, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <copyright-holder>Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <!--author-paid-->
          <license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p>
        </license>
      </permissions>
      <abstract>
        <p>Neonatal cholestasis is a potentially life-threatening condition requiring prompt diagnosis. Mutations in several different genes can cause progressive familial intrahepatic cholestasis, but known genes cannot account for all familial cases. Here we report four individuals from two unrelated families with neonatal cholestasis and mutations in <italic>NR1H4</italic>, which encodes the farnesoid X receptor (FXR), a bile acid-activated nuclear hormone receptor that regulates bile acid metabolism. Clinical features of severe, persistent <italic>NR1H4</italic>-related cholestasis include neonatal onset with rapid progression to end-stage liver disease, vitamin K-independent coagulopathy, low-to-normal serum gamma-glutamyl transferase activity, elevated serum alpha-fetoprotein and undetectable liver bile salt export pump (<italic>ABCB11</italic>) expression. Our findings demonstrate a pivotal function for FXR in bile acid homeostasis and liver protection.</p>
      </abstract>
      <abstract abstract-type="web-summary">
        <p>
<inline-graphic id="i1" xlink:href="ncomms10713-i1.jpg"/>Neonatal cholestasis is a result of elevated bile acid levels, and is associated with mutations in genes regulating bile acid homeostasis. Here the authors identify mutations in the bile acid sensing farnesoid X receptor in four individuals with neonatal cholestasis from two unrelated families.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <p>Bile acids are detergents that are produced in the liver and released into the gut to facilitate and promote absorption of lipid nutrients. They are reabsorbed in the gut along with the nutrients and returned to the liver via the portal vein. Excessive bile acid levels are toxic, and both their hepatic production and enterohepatic circulation are stringently regulated. Bile acid levels are sensed by a nuclear bile acid receptor termed the farnesoid X receptor (FXR), encoded by the <italic>NR1H4</italic> gene. Elevated bile acid levels activate FXR to induce a program that represses hepatocyte bile acid biosynthesis and uptake while increasing export<xref ref-type="bibr" rid="b1">1</xref><xref ref-type="bibr" rid="b2">2</xref>.</p>
    <p>This suppression of bile acid production makes FXR a therapeutic target for cholestatic liver disease, and clinical trials of FXR agonists in primary biliary cirrhosis are promising<xref ref-type="bibr" rid="b3">3</xref><xref ref-type="bibr" rid="b4">4</xref><xref ref-type="bibr" rid="b5">5</xref>. FXR activation suppresses autophagy<xref ref-type="bibr" rid="b6">6</xref> and affects additional metabolic targets outside of bile acid homeostasis, and FXR ligands have beneficial effects in mouse models of metabolic disease<xref ref-type="bibr" rid="b7">7</xref><xref ref-type="bibr" rid="b8">8</xref>. In accord with this, FXR has been identified as a potential mediator of the rapidly beneficial metabolic effects of bariatric surgery in mice<xref ref-type="bibr" rid="b9">9</xref>, and initial clinical results indicate that FXR agonists may have beneficial effects in non-alcoholic fatty liver disease and the metabolic syndrome<xref ref-type="bibr" rid="b10">10</xref><xref ref-type="bibr" rid="b11">11</xref>. Thus, FXR is both a key modulator of multiple metabolic and hepatocyte-protective pathways and an emerging therapeutic target for both cholestatic and metabolic diseases.</p>
    <p>Mutations in several genes encoding proteins involved in bile acid homeostasis cause neonatal cholestasis. Progressive familial intrahepatic cholestasis (PFIC) types 1, 2 and 3 are a group of cholestatic conditions caused by mutations in <italic>ATP8B1, ABCB11</italic> and <italic>ABCB4</italic> respectively, and defects in <italic>TJP2</italic>, encoding tight junction protein 2, can also cause severe cholestatic liver disease<xref ref-type="bibr" rid="b12">12</xref>. Multiple heterozygous variants in known PFIC genes may contribute to disease in some cases<xref ref-type="bibr" rid="b13">13</xref>, but up to one third of cases remain idiopathic<xref ref-type="bibr" rid="b14">14</xref>. Patients with PFIC1 or PFIC2 and patients with <italic>TJP2</italic> mutations characteristically present with low-to-normal serum gamma-glutamyl transferase (GGT) activity<xref ref-type="bibr" rid="b12">12</xref><xref ref-type="bibr" rid="b15">15</xref>. Both <italic>ABCB11</italic>, which encodes the bile salt export pump (BSEP) and is deficient in PFIC2, and <italic>ABCB4,</italic> which encodes multidrug resistance protein 3, MDR3, and is deficient in PFIC3, are direct targets of FXR. Variants of <italic>NR1H4</italic>, located at 12q23.1, have been associated with increased risk for intrahepatic cholestasis of pregnancy<xref ref-type="bibr" rid="b16">16</xref>. A recent search for functional <italic>NR1H4</italic> variation in cholestatic patients found none<xref ref-type="bibr" rid="b17">17</xref>, but a heterozygous <italic>NR1H4</italic> variant has been reported in one patient with infantile cholestasis<xref ref-type="bibr" rid="b18">18</xref>. Here we describe four patients from two families with homozygous loss of <italic>NR1H4</italic> function and severe neonatal cholestasis.</p>
    <sec disp-level="1">
      <title>Results</title>
      <p>Whole-exome sequencing and single-nucleotide polymorphism (SNP) arrays of two unrelated probands with severe cholestasis revealed homozygous loss of function mutations in <italic>NR1H4</italic>, located at 12q23.1. Further analysis confirmed the same <italic>NR1H4</italic> genotype for an additional affected individual in each family (<xref ref-type="table" rid="t1">Table 1</xref>). All patients presented with liver dysfunction at an early age (<xref ref-type="table" rid="t1">Table 1</xref>). Three presented with neonatal cholestasis; patient 4 presented with ascites, pleural effusions and intraventricular haemorrhage at birth. At the time of initial evaluation all patients had conjugated hyperbilirubinemia, elevated aminotransferases, low-to-normal GGT and elevated prothrombin time and international normalized ratio (<xref ref-type="table" rid="t1">Table 1</xref> and <xref ref-type="supplementary-material" rid="S1">Supplementary Table 1</xref>). Factors V and VII levels in patients 1 and 3 and were markedly reduced. Alpha-fetoprotein, measured in three patients, was strikingly increased early in the course of the disease and trended down with time. Serum bile acids were elevated in patient 1. Patients 1â3 developed liver failure in the first 2 years of life with worsening coagulopathy, hypoglycemia and hyperammonemia. Both patients in family 1 underwent deceased donor liver transplants, while patient 3 died awaiting transplantation. Patient 4 died at 5 weeks from complications from an aortic thrombus.</p>
      <p>Histological examination of the liver in all four patients showed ductular reaction, diffuse giant cell transformation and ballooning of hepatocytes and intralobular cholestasis (<xref ref-type="fig" rid="f1">Fig. 1</xref>). The degree of inflammatory cell infiltration and fibrosis varied with the progression of the disease, but the explanted liver of patient 1 showed micronodular cirrhosis and fibrosis was evident at later stages for all patients. Autopsy of patient 3 revealed siderosis in the liver, pancreas, heart and thyroid gland (<xref ref-type="supplementary-material" rid="S1">Supplementary Fig. 1</xref>) suggesting gestational alloimmune liver disease, but immunohistochemical studies did not support this diagnosis<xref ref-type="bibr" rid="b19">19</xref>. Liver immunohistochemistry showed no detectable expression of BSEP in bile canaliculi in all patients, but expression of the phospholipid transporter MDR3 was preserved (<xref ref-type="fig" rid="f1">Fig. 1</xref>). Additional immunohistochemical studies in patient 1 showed normal expression of alanyl aminopeptidase, GGT and MRP2, as well as increased perisinusoidal and perihepatocytic reticulin (<xref ref-type="supplementary-material" rid="S1">Supplementary Fig. 2</xref>). Although these results suggested <italic>ABCB11</italic> deficiency, sequencing and deletionâduplication analysis of <italic>ABCB11</italic> in patient 1 was negative.</p>
      <p>Whole-exome sequencing of patient 2 (family 1) identified an apparently homozygous c.526C&gt;T (p.R176*) mutation in <italic>NR1H4</italic> that prematurely terminates the protein at amino acid 176 (nucleotide: NM_005123 and protein: NP_005114) in the DNA-binding domain (DBD). The same homozygous mutation was found in patient 1; both asymptomatic parents are carriers (<xref ref-type="fig" rid="f2">Fig. 2a</xref> and <xref ref-type="table" rid="t2">Table 2</xref>). Consanguinity in this family was confirmed by cSNP array detection of â¼89âMb of total homozygous regions larger than 5âMb each in patient 1. The predicted residual protein fragment lacks both DNA binding and hormone receptor domains, and immunohistochemistry showed no FXR expression (<xref ref-type="fig" rid="f1">Fig. 1</xref>). This variant has been reported previously in one patient with infantile cholestasis as a heterozygous change<xref ref-type="bibr" rid="b18">18</xref> but the heterozygous family 1 parents had normal liver biochemistry. The mother did not have symptoms of cholestasis in any of her three pregnancies.</p>
      <p>Whole-exome sequencing of patient 4 (family 2) identified an apparently homozygous in-frame insertion variant c.419_420insAAA (p.Tyr139_Asn140insLys) in <italic>NR1H4</italic>, which was also demonstrated in patient 3 (<xref ref-type="fig" rid="f2">Fig. 2b</xref>). Despite the expected expression of the in-frame insertion mutant product, FXR protein was undetectable in both patients (<xref ref-type="fig" rid="f1">Fig. 1</xref>). The mother carried the in-frame insertion in <italic>NR1H4</italic> and the father was negative. A SNP array suggested copy number loss (<xref ref-type="supplementary-material" rid="S1">Supplementary Fig. 3</xref>), and breakpoint junction PCR showed that both patients carry a paternally inherited 31.7âkb deletion within the <italic>NR1H4</italic> gene (<xref ref-type="fig" rid="f2">Fig. 2c,d</xref>). This deletion spans the first two coding exons of all transcripts of <italic>NR1H4</italic> and is predicted to produce a complete loss of FXR expression. Patient 4 was also heterozygous for a c.197G&gt;A (p.Trp66*) predicted pathogenic variant in <italic>SLC10A2</italic>, encoding the ileal apical sodium-dependent bile acid transporter (ASBT). This variant was absent in patient 3 (<xref ref-type="table" rid="t2">Table 2</xref>). Patient 4 was also found to be homozygous for the common c.1331T&gt;C (p.V444A) variant in <italic>ABCB11</italic>. Patient 3 was heterozygous for this allele, which was not present in family 1 (<xref ref-type="table" rid="t2">Table 2</xref>).</p>
      <p>The c.419_420insAAA (p.Tyr139_Asn140insLys) insertion is located in the first zinc-binding module of the FXR DBD close to the DNA-recognition helix (<xref ref-type="fig" rid="f3">Fig. 3a,b</xref>). This region of the DBD is highly conserved in vertebrate nuclear receptors (<xref ref-type="supplementary-material" rid="S1">Supplementary Fig. 4</xref>), suggesting that this insertion disrupts DNA binding. Although expression of the mutant protein was not detected immunohistochemically, it might be expressed at low levels. Therefore, both wild-type and insertion mutant FXR were produced by <italic>in vitro</italic> translation, along with the retinoid X receptor (RXRÎ±) heterodimer partner, and FXR/RXR DNA binding was assessed using an electrophoretic mobility-shift assay. The mutant FXR showed no detectable binding to a consensus FXR/RXR-binding site containing an inverted repeat of the receptor-binding hexamer separated by one base pair (IR-1) or the IR-1 element from the <italic>SHP</italic> promoter (<xref ref-type="fig" rid="f3">Fig. 3c</xref>). The insertion also abolished transcriptional activity in response to the synthetic agonist GW4064 on a synthetic promoter containing three copies of a consensus IR-1 (<xref ref-type="fig" rid="f3">Fig. 3d</xref>). In addition to this IR-1 transactivation, we have recently reported that FXR can transcriptionally repress expression of autophagic genes via a distinct DR-1 direct repeat element<xref ref-type="bibr" rid="b6">6</xref>. The mutant protein was also defective in this function (<xref ref-type="supplementary-material" rid="S1">Supplementary Fig. 5</xref>).</p>
      <p>In addition to the liver, FXR is highly expressed in the small intestine where it regulates FGF19, a hormonal growth factor that acts in the liver to decrease bile acid synthesis by repressing expression of the biosynthetic enzyme CYP7A1 (ref. <xref ref-type="bibr" rid="b20">20</xref>). Consistent with absent intestinal FXR, the surviving family 1 patients have low serum FGF19 (31.6Â±6âpgâml<sup>â1</sup>; pediatric normal 220Â±35 (ref. <xref ref-type="bibr" rid="b21">21</xref>)) accompanied by high CYP7A1 activity, as evidenced by high serum levels of the bile acid precursor C4 (211.8Â±124; pediatric normal 22.8Â±15.8ângâml<sup>â1</sup> (ref. <xref ref-type="bibr" rid="b22">22</xref>)), and low cholesterol (63Â±8âmgâdl<sup>â1</sup>) (<xref ref-type="supplementary-material" rid="S1">Supplementary Fig. 6dâf</xref>). These patients also have persistent serum bilirubin and liver enzyme abnormalities (<xref ref-type="supplementary-material" rid="S1">Supplementary Fig. 6aâc</xref>) and histological evidence of progressive steatosis. It is possible that their mild post-transplant hepatopathy is a consequence of the disruption of normal enterohepatic bile acid homeostasis. Post-transplant progressive hepatic steatosis has also been reported for PFIC1 (refs <xref ref-type="bibr" rid="b23">23</xref>, <xref ref-type="bibr" rid="b24">24</xref>), perhaps due to altered FXR signaling<xref ref-type="bibr" rid="b25">25</xref>.</p>
      <p>All patients presented with severe vitamin K-independent coagulopathy early in the course of their disease. This is consistent with a recent genome-wide ChIP-Seq DNA binding study that identified the complement and coagulation cascades as direct regulatory targets of FXR in human primary hepatocytes<xref ref-type="bibr" rid="b26">26</xref>, and also with earlier reports that human FXR induces expression of fibrinogen<xref ref-type="bibr" rid="b27">27</xref> and kininogen<xref ref-type="bibr" rid="b28">28</xref>. We confirmed that FXR agonists induce mRNA expression of all three fibrinogen genes <italic>FGA</italic>, <italic>FGB</italic> and <italic>FGG</italic>, and also increase expression of the genes encoding tissue factor/factor III/thromboplastin (<italic>F3</italic>), factor XII/Hageman factor (<italic>F12</italic>), and factor XIII B (<italic>F13B</italic>) in the human liver cell line Huh7 (<xref ref-type="supplementary-material" rid="S1">Supplementary Fig. 7a</xref>). These responses were decreased by FXR knockdown (<xref ref-type="supplementary-material" rid="S1">Supplementary Fig. 7b</xref>).</p>
    </sec>
    <sec disp-level="1">
      <title>Discussion</title>
      <p>We conclude that homozygous loss of FXR function due to <italic>NR1H4</italic> mutations causes a low GGT form of severe PFIC. The clinical features of <italic>NR1H4</italic>-related cholestasis include neonatal onset with rapid progression to end-stage liver disease, early onset vitamin K-independent coagulopathy, low-to-normal serum GGT, elevated serum alpha-fetoprotein and undetectable liver BSEP expression. The lack of elevation of GGT is consistent with the loss of BSEP expression. BSEP, encoded by <italic>ABCB11</italic>, was the first identified FXR target gene. The BSEP promoter is particularly responsive to FXR activation<xref ref-type="bibr" rid="b29">29</xref>, suggesting that the absence of BSEP expression is a direct consequence of the loss of FXR function. Expression of MDR3, which is less responsive to FXR<xref ref-type="bibr" rid="b30">30</xref>, was retained.</p>
      <p>The basis for the more severe symptoms of both patients in family 2, and the hydropic presentation in patient 4, is not clear. Homozygous loss of ASBT/<italic>SLC10A2</italic> function causes bile acid malabsorption as early as the second day of life<xref ref-type="bibr" rid="b31">31</xref> and ASBT haploinsufficiency could further disrupt bile acid homeostasis in the context of an increased prenatal bile acid pool. Thus, heterozygosity for a pathogenic variant in the <italic>SLC10A2</italic> gene could contribute to the severe pathology of patient 4. This patient was also homozygous for a common <italic>ABCB11</italic> c.1331T&gt;C (p.V444A) variant, which has been associated with increased risk for several forms of intrahepatic cholestasis<xref ref-type="bibr" rid="b32">32</xref>. However, the lack of detectable BSEP protein expression in all four patients argues against a functional impact of this polymorphism in patients 3 or 4. The absence of detectable FXR expression also argues against a potential dominant negative impact of the p.Tyr139_Asn140insLys insertion mutant protein.</p>
      <p>Since both family 1 parents are heterozygous for the p.R176* truncation but do not show liver dysfunction, our results are not consistent with a prior report of severe infantile cholestasis in an individual heterozygous for the same mutation<xref ref-type="bibr" rid="b18">18</xref>. Even if the short mutant peptide were expressed, it lacks both the DBD and ligand-binding domain and there is no obvious mechanism for it to exert a dominant negative effect. This simple loss of function would therefore be expected to be recessive to the wild-type allele, as observed for both of the family 1 parents, both of the heterozygous family 2 parents, and also in mice lacking a single <italic>NR1H4</italic> allele. One possibility is that the proband in the prior report harboured an additional, undetected mutation affecting the other <italic>NR1H4</italic> allele. However, this patient had elevated serum GGT levels<xref ref-type="bibr" rid="b18">18</xref>, which is not consistent with the four individuals presented here with confirmed biallelic loss of <italic>NR1H4</italic>. Thus, the earlier patient may have had a deleterious mutation in another gene associated with cholestasis, as observed in patient 4, or more generally some other problem that compromised liver function. Overall, it is apparent that heterozygous loss of FXR function is not sufficient to cause infantile cholestasis.</p>
      <p>The coagulopathy observed in all four patients could be interpreted as a simple consequence of their liver disease or could be secondary to a problem with absorption of lipid-soluble nutrients, particularly vitamin K, which is essential for clotting. However, four distinct but complementary lines of evidence argue that it is a direct consequence of the loss of FXR function. The first is that coagulopathy was observed very early in the course of their disease, well before end-stage liver failure. This early onset coagulopathy was not responsive to vitamin K treatment. The second is that several prior studies have suggested such a function for FXR. Initial reports indicating that human FXR induces expression of fibrinogen<xref ref-type="bibr" rid="b27">27</xref> and kininogen<xref ref-type="bibr" rid="b28">28</xref> were strongly reinforced by a more recent ChIP-Seq analysis of the FXR cistrome in human primary hepatocytes, which identified multiple components of the complement and coagulation cascades as specifically enriched FXR targets<xref ref-type="bibr" rid="b26">26</xref>. We confirmed FXR-dependent induction of all three fibrinogen genes and at least three additional coagulation factors in a human liver cell line (<xref ref-type="supplementary-material" rid="S1">Supplementary Fig. 7</xref>). The third is an increase in coagulation rate in patients treated with the FXR agonist obeticholic acid, as indicated by a modest but significant decrease in the international normalized ratio<xref ref-type="bibr" rid="b11">11</xref>. In accord with this, the fourth is a recent report of increased coagulability in patients with a range of cholestatic disorders<xref ref-type="bibr" rid="b33">33</xref>. This was considered paradoxical from the perspective of liver failure, but in the current context is a directly predicted consequence of FXR activation by elevated bile acids. Consistent with this characterization of a broader range of patients, vitamin K-independent coagulopathy is not a common early finding for the PFIC group of disorders<xref ref-type="bibr" rid="b34">34</xref>. Thus, our patient data, the direct role of FXR in regulating coagulation, and clinical studies in obeticholic acid treated patients and in other forms of cholestasis all suggest early onset, vitamin K-independent coagulopathy as a distinguishing diagnostic feature of <italic>NR1H4</italic>-reated cholestasis.</p>
      <p>The surviving patients in family 1 are genetically mosaic, with wild-type FXR expressed only in the liver. Since they do not show obvious pathology in other organs known to express FXR, including intestine and kidney, such extrahepatic FXR function is not essential. However, it is likely that the absence of FXR in the intestine accounts for their very low levels of circulating FGF19. In turn, the loss of this negative feedback regulator likely accounts for their increased bile acid synthesis, moderately elevated liver enzymes and hepatic steatosis.</p>
      <p>In contrast to the severe disease of the human patients, loss of FXR function in mice results in only a modest elevation of bile acid levels that does not cause liver failure<xref ref-type="bibr" rid="b35">35</xref><xref ref-type="bibr" rid="b36">36</xref>. One potential explanation for this is that mice have an additional FXR isoform, FXRÎ², encoded by <italic>NrIh5</italic> (ref. <xref ref-type="bibr" rid="b37">37</xref>). <italic>NR1H5</italic> is a pseudogene in humans, with multiple in frame stop codons and also frame shifts in the predicted transcript. Although very little is known about the function of FXRÎ², it is likely that it overlaps with that of FXRÎ±/<italic>NrIh4</italic>. Thus, it is possible that FXRÎ² expression partially compensates for the loss of FXRÎ±/<italic>NrIh4</italic> in mice.</p>
      <p>Overall, the development of early cholestasis and rapidly progressive hepatic dysfunction in humans with mutations in the <italic>NR1H4</italic> gene reinforces the role of FXR as a master regulator of bile acid homeostasis, and confirms a key role in hepatoprotection by preventing bile acid-induced liver toxicity. We predict that some of the patients that show PFIC characteristics with normal GGT and without identified mutations in known PFIC genes<xref ref-type="bibr" rid="b12">12</xref><xref ref-type="bibr" rid="b34">34</xref> will carry loss-of-function variants in <italic>NR1H4</italic>, and that these patients may be clinically distinguished by their early onset, vitamin K-independent coagulopathy and rapid progression.</p>
    </sec>
    <sec disp-level="1">
      <title>Methods</title>
      <sec disp-level="2">
        <title>Clinical whole-exome sequencing</title>
        <p>Subjects were enrolled in research studies approved by the institutional review boards of Baylor College of Medicine or Stanford University School of Medicine, and informed consent was obtained. Clinical whole-exome sequencing was performed as described previously<xref ref-type="bibr" rid="b38">38</xref>. Briefly, genomic DNA samples were fragmented by sonication, ligated to multiplexing paired-end adapters, amplified by PCR and hybridized to a solution-based exome capture library that was designed in-house. Enriched DNA products were paired-end sequenced (100âbp) on an Illumina HiSeq 2000 platform, with a mean coverage of &gt; Ã 130 and at least Ã 20 coverage for &gt;95% of the target regions. The data were analysed and annotated by a pipeline developed in-house. All samples underwent cSNP array analysis performed with human exome BeadChip (Illumina, San Diego, CA) according to manufacturer's instructions.</p>
      </sec>
      <sec disp-level="2">
        <title>Breakpoint junction PCR</title>
        <p>To map the junction of the deletion, serial pairs of primers were designed with about 15âkb intervals that flanked the estimated minimal deletion region as defined by cSNP array result. PCR was performed with Qiagen LongRange PCR kit (Qiagen, Valencia, CA). This strategy yielded amplicons no more than 20âkb in length, ensuring PCR amplification failure without inter-pair deletion. With successful amplification, addition primer sets were designed within that region to generate PCR products less than 1,000âbp in length for Sanger sequencing confirmation.</p>
      </sec>
      <sec disp-level="2">
        <title>Protein sequence alignment and structure prediction</title>
        <p>Protein sequences were retrieved from UniProt (<ext-link ext-link-type="uri" xlink:href="http://www.uniprot.org">www.uniprot.org</ext-link>). Sequence alignment was performed with Clustal X (ref. <xref ref-type="bibr" rid="b39">39</xref>). Predictive structures of wild type FXR and FXR mutant with in-frame insertion were generated with RaptorX (ref. <xref ref-type="bibr" rid="b40">40</xref>) and compared with the structure of EcR/RXR DBD in complex with IR-1 (PBD 1R0N) (ref. <xref ref-type="bibr" rid="b41">41</xref>).</p>
      </sec>
      <sec disp-level="2">
        <title>Electrophoretic mobility-shift assay</title>
        <p>Electrophoretic mobility-shift assay was performed as described<xref ref-type="bibr" rid="b5">5</xref> with modifications as below. Double-stranded oligonucleotides (consensus FXRE/IR1 and SHP/IR1, 5â²-GATGGGCCAAGGTCAATGACCTCGGGG-3â² and 5â²-CCCTGGTACAGCCTGGGTTAATGACCCTGTTTATGCACTTG-3â², respectively) were end-labelled with [Î³-32P] ATP (3,000âCi per mmol) using T4 polynucleotide kinase for probe labelling. Human FXR and RXRÎ± proteins (<xref ref-type="fig" rid="f2">Fig. 2c</xref>) were prepared with a TNT T7 Quick coupled system (Promega, Madison, WI). <italic>In vitro</italic> translated proteins were incubated with 0.05âng of probe in the binding reaction buffer containing 10âmM Tris (pH 8.0), 60âmM KCl, 0.1% NP-40, 6% glycerol, 1âmM dithiothreitol and1âÎ¼g of poly(dI-dC) on ice for 20âmin. DNA-protein complexes were resolved on standard non-denaturing 4% polyacrylamide gels. The gels were dried and exposed to X-ray film at â80âÂ°C for 5â24âh.</p>
      </sec>
      <sec disp-level="2">
        <title>FXR transactivation assay</title>
        <p>Hela cells and AML12 cells were maintained in DMEM with 10% fetal bovine serum (FBS) at 37âÂ°C, 5% CO2. For Hela cell transfection, cells were seeded to 12-well plates and transfected with 1âÎ¼g reporter vector (pGL3-FXREx3) and 50âng per 100âng of pCMX-hFXR, pCMX-hFXR mutant, pCMX-hRXRÎ±, respectively, using iM Fectin (GenDEPOT, Barker, TX) according to manufacturer's instructions. For internal control, 10âng of beta-galactosidase plasmid was cotransfected. Three hours after transfection, cells were treated with vehicle (dimethyl sulfoxide) or 1âÎ¼M synthetic FXR agonist GW4064 (Sigma-Aldrich, St Louis, MO) and incubated for additional 24âh. Finally cells lysates were collected and luciferase activities were measured as described previously<xref ref-type="bibr" rid="b42">42</xref>. For AML12 transfection, cells were seeded to 24-well plates and transfected with 200âng of reporter vector (pGL3-DR1x3 and pGL3-LC3ax3), 100âng of p(CMX)-mPPARÎ±, or pCMX- hFXR, and 50âng of CMX-Î²-galactosidase. After 4âh transfection, cells were treated with or vehicle (0.1% DMSO) using Lipofectamine 2000 (Invitrogen), 10âÎ¼M Wy-14,643 or 1âÎ¼M GW4064 in media containing charcoal-stripped serum for 20âh before performing luciferase and Î²-galactosidase assay.</p>
      </sec>
      <sec disp-level="2">
        <title>siRNA transfection</title>
        <p>Huh7 cells were maintained in DMEM supplemented with 10% FBS (Life technologies). For ligand treatment, media were replaced with phenol red-free DMEM supplemented 5% charcoal-stripped FBS (Life technologies) then FXR ligands (CDCA, Sigma, C-9377; GW4064, Tocris bioscience, #2473) were treated for 24âh. The siRNAs targeting human FXR (Dharmacon, L-003414-00-0005) were transfected with Lipofectamine 2000 (Life technologies) according to the manufacturer's protocol. After 24âh, media were replaced with phenol red-free DMEM containing 5% chacoal-stripped FBS then FXR ligands were treated for following 48âh.</p>
      </sec>
      <sec disp-level="2">
        <title>RNA isolation and real-time PCR analysis</title>
        <p>Total RNA was isolated using Quick-RNA MiniPrep Kit (Zymo Research, #11-328) and cDNA was prepared using amfiRivert cDNA Synthesis Platinum Master Mix (GenDEPOT, #5600). Gene expression level was determined by real-time PCR using LightCycler 480 Real-Time PCR System (Roche) with PerfeCTa SYBR Green FastMix (Quanta Biosciences). Expression values were normalized to GAPDH mRNA. Primer sets are listed in <xref ref-type="table" rid="t3">Table 3</xref>.</p>
      </sec>
      <sec disp-level="2">
        <title>FGF19 measurements</title>
        <p>Serum FGF19 was measured on frozen fasting serum samples from patients 1 and 2 and healthy young adults by quantitative sandwich enzyme-linked immunosorbent assay, using a commercially available kit (FGF19 Quantikine ELISA kit, Cat No. DF1900; R&amp;D Systems, Minneapolis, MN), and following the manufacturer's instructions. We performed two independent measurements where 100âÎ¼l of serum were used and all samples were assayed in triplicate.</p>
      </sec>
      <sec disp-level="2">
        <title>Measurement of serum 7-alpha-hydroxy-4-cholesten-3-one (C4)</title>
        <p>C4 was measured in frozen fasting serum samples from patients 1 and 2 and healthy young adults. Measurements were determined using a high-performance liquid chromatography-tandem mass spectrometry as previosuly described<xref ref-type="bibr" rid="b43">43</xref>.</p>
      </sec>
    </sec>
    <sec disp-level="1">
      <title>Author contibutions</title>
      <p>N.G.-O., C.J.P., R.X. F.X., B.L.S., G.M.E. and D.D.M. conceived, designed and directed the study. N.G.-O., C.J.P., B.L.S., K.M., J.L.P., T.A.J., G.C.W., M.P., W.E.B., R.J.S. and N.K. saw patients or collected or analysed patient samples. R.X and F.X. designed, performed and interpreted genetic analyses, with substantial contributions from J.Z., W.H., P.L., D.M.M., E.B., J.R.L., S.E.P., R.A.G., C.M.E. and Y.Y. A.S.K. and M.J.F. carried out histological analysis. N.G-O., R.X. and D.D.M. wrote the manuscript, with substantial contributions from C.J.P, B.L.S, A.S.K. and M.J.F. All authors approved the final manuscript and contributed to its intellectual content.</p>
    </sec>
    <sec disp-level="1">
      <title>Additional information</title>
      <p><bold>Accession codes:</bold> Whole exome sequencing data for the pathogenic <italic>NR1H4</italic> variants have been deposited in the NCBI ClinVar database under accession codes SCV000258398, SCV000258399 and SCV000258400.</p>
      <p><bold>How to cite this article:</bold> Gomez-Ospina, N. <italic>et al.</italic> Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. <italic>Nat. Commun.</italic> 7:10713 doi: 10.1038/ncomms10713 (2016).</p>
    </sec>
    <sec sec-type="supplementary-material" id="S1">
      <title>Supplementary Material</title>
      <supplementary-material id="d33e18" content-type="local-data">
        <caption>
          <title>Supplementary Information</title>
          <p>Supplementary Figures 1-7 and Supplementary Tables 1-2</p>
        </caption>
        <media xlink:href="ncomms10713-s1.pdf"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>Supported by a NURSA Data Source Project (NDSP) grant from NIDDK and the Robert R. P. Doherty Jr. Welch Chair in Science (Q-022) to D.D.M. and supported in part by the US National Human Genome Research Institute (NHGRI)/National Heart Lung and Blood Institute (NHLBI) Grant No.U54HG006542 to the Baylor-Hopkins Center for Mendelian Genomics (BHCMG).</p>
    </ack>
    <ref-list>
      <ref id="b1">
        <mixed-citation publication-type="journal"><name><surname>Matsubara</surname><given-names>T.</given-names></name>, <name><surname>Li</surname><given-names>F.</given-names></name> &amp; <name><surname>Gonzalez</surname><given-names>F. J.</given-names></name>
<article-title>FXR signaling in the enterohepatic system</article-title>. <source>Mol. Cell. Endocrinol.</source>
<volume>368</volume>, <fpage>17</fpage>â<lpage>29</lpage> (<year>2013</year>) .<pub-id pub-id-type="pmid">22609541</pub-id></mixed-citation>
      </ref>
      <ref id="b2">
        <mixed-citation publication-type="journal"><name><surname>Kuipers</surname><given-names>F.</given-names></name>, <name><surname>Bloks</surname><given-names>V. W.</given-names></name> &amp; <name><surname>Groen</surname><given-names>A. K.</given-names></name>
<article-title>Beyond intestinal soap--bile acids in metabolic control</article-title>. <source>Nat. Rev. Endocrinol.</source>
<volume>10</volume>, <fpage>488</fpage>â<lpage>498</lpage> (<year>2014</year>) .<pub-id pub-id-type="pmid">24821328</pub-id></mixed-citation>
      </ref>
      <ref id="b3">
        <mixed-citation publication-type="journal"><name><surname>Lindor</surname><given-names>K. D.</given-names></name>
<article-title>Farnesoid X receptor agonists for primary biliary cirrhosis</article-title>. <source>Curr. Opin. Gastroenterol.</source>
<volume>27</volume>, <fpage>285</fpage>â<lpage>288</lpage> (<year>2011</year>) .<pub-id pub-id-type="pmid">21297469</pub-id></mixed-citation>
      </ref>
      <ref id="b4">
        <mixed-citation publication-type="journal"><name><surname>Poupon</surname><given-names>R.</given-names></name>
<article-title>Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action</article-title>. <source>Clin. Res. Hepatol. Gastroenterol.</source>
<volume>36</volume>, (Suppl 1): <fpage>S3</fpage>â<lpage>12</lpage> (<year>2012</year>) .<pub-id pub-id-type="pmid">23141891</pub-id></mixed-citation>
      </ref>
      <ref id="b5">
        <mixed-citation publication-type="journal"><name><surname>Hirschfield</surname><given-names>G. M.</given-names></name>
<italic>et al.</italic>
<article-title>Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid</article-title>. <source>Gastroenterology</source>
<volume>148</volume>, <fpage>751</fpage>â<lpage>761 e758</lpage> (<year>2015</year>) .<pub-id pub-id-type="pmid">25500425</pub-id></mixed-citation>
      </ref>
      <ref id="b6">
        <mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>J. M.</given-names></name>
<italic>et al.</italic>
<article-title>Nutrient-sensing nuclear receptors coordinate autophagy</article-title>. <source>Nature</source>
<volume>516</volume>, <fpage>112</fpage>â<lpage>115</lpage> (<year>2014</year>) .<pub-id pub-id-type="pmid">25383539</pub-id></mixed-citation>
      </ref>
      <ref id="b7">
        <mixed-citation publication-type="journal"><name><surname>Watanabe</surname><given-names>M.</given-names></name>
<italic>et al.</italic>
<article-title>Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c</article-title>. <source>J. Clin. Invest.</source>
<volume>113</volume>, <fpage>1408</fpage>â<lpage>1418</lpage> (<year>2004</year>) .<pub-id pub-id-type="pmid">15146238</pub-id></mixed-citation>
      </ref>
      <ref id="b8">
        <mixed-citation publication-type="journal"><name><surname>Fang</surname><given-names>S.</given-names></name>
<italic>et al.</italic>
<article-title>Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance</article-title>. <source>Nat. Med.</source>
<volume>21</volume>, <fpage>159</fpage>â<lpage>165</lpage> (<year>2015</year>) .<pub-id pub-id-type="pmid">25559344</pub-id></mixed-citation>
      </ref>
      <ref id="b9">
        <mixed-citation publication-type="journal"><name><surname>Ryan</surname><given-names>K. K.</given-names></name>
<italic>et al.</italic>
<article-title>FXR is a molecular target for the effects of vertical sleeve gastrectomy</article-title>. <source>Nature</source>
<volume>509</volume>, <fpage>183</fpage>â<lpage>188</lpage> (<year>2014</year>) .<pub-id pub-id-type="pmid">24670636</pub-id></mixed-citation>
      </ref>
      <ref id="b10">
        <mixed-citation publication-type="journal"><name><surname>Mudaliar</surname><given-names>S.</given-names></name>
<italic>et al.</italic>
<article-title>Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease</article-title>. <source>Gastroenterology</source>
<volume>145</volume>, <fpage>574</fpage>â<lpage>582 e571</lpage> (<year>2013</year>) .<pub-id pub-id-type="pmid">23727264</pub-id></mixed-citation>
      </ref>
      <ref id="b11">
        <mixed-citation publication-type="journal"><name><surname>Neuschwander-Tetri</surname><given-names>B. A.</given-names></name>
<italic>et al.</italic>
<article-title>Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial</article-title>. <source>Lancet</source>
<volume>385</volume>, <fpage>956</fpage>â<lpage>965</lpage> (<year>2015</year>) .<pub-id pub-id-type="pmid">25468160</pub-id></mixed-citation>
      </ref>
      <ref id="b12">
        <mixed-citation publication-type="journal"><name><surname>Sambrotta</surname><given-names>M.</given-names></name>
<italic>et al.</italic>
<article-title>Mutations in TJP2 cause progressive cholestatic liver disease</article-title>. <source>Nat. Genet.</source>
<volume>46</volume>, <fpage>326</fpage>â<lpage>328</lpage> (<year>2014</year>) .<pub-id pub-id-type="pmid">24614073</pub-id></mixed-citation>
      </ref>
      <ref id="b13">
        <mixed-citation publication-type="journal"><name><surname>Goldschmidt</surname><given-names>M. L.</given-names></name>
<italic>et al.</italic>
<article-title>Increased frequency of double and triple heterozygous gene variants in children with intrahepatic cholestasis</article-title>. <source>Hepatol. Res</source> doi:10.1111/hepr.12545 (<year>2015</year>) .</mixed-citation>
      </ref>
      <ref id="b14">
        <mixed-citation publication-type="journal"><name><surname>Fischler</surname><given-names>B.</given-names></name> &amp; <name><surname>Lamireau</surname><given-names>T.</given-names></name>
<article-title>Cholestasis in the newborn and infant</article-title>. <source>Clin. Res. Hepatol. Gastroenterol.</source>
<volume>38</volume>, <fpage>263</fpage>â<lpage>267</lpage> (<year>2014</year>) .<pub-id pub-id-type="pmid">24746684</pub-id></mixed-citation>
      </ref>
      <ref id="b15">
        <mixed-citation publication-type="journal"><name><surname>Jacquemin</surname><given-names>E.</given-names></name>
<article-title>Progressive familial intrahepatic cholestasis</article-title>. <source>Clin. Res. Hepatol. Gastroenterol.</source>
<volume>36</volume>, (Suppl 1): <fpage>S26</fpage>â<lpage>S35</lpage> (<year>2012</year>) .<pub-id pub-id-type="pmid">23141890</pub-id></mixed-citation>
      </ref>
      <ref id="b16">
        <mixed-citation publication-type="journal"><name><surname>Van Mil</surname><given-names>S. W.</given-names></name>
<italic>et al.</italic>
<article-title>Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy</article-title>. <source>Gastroenterology</source>
<volume>133</volume>, <fpage>507</fpage>â<lpage>516</lpage> (<year>2007</year>) .<pub-id pub-id-type="pmid">17681172</pub-id></mixed-citation>
      </ref>
      <ref id="b17">
        <mixed-citation publication-type="journal"><name><surname>Davit-Spraul</surname><given-names>A.</given-names></name>, <name><surname>Gonzales</surname><given-names>E.</given-names></name> &amp; <name><surname>Jacquemin</surname><given-names>E.</given-names></name>
<article-title>NR1H4 analysis in patients with progressive familial intrahepatic cholestasis, drug-induced cholestasis or intrahepatic cholestasis of pregnancy unrelated to ATP8B1, ABCB11 and ABCB4 mutations</article-title>. <source>Clin. Res. Hepatol. Gastroenterol.</source>
<volume>36</volume>, <fpage>569</fpage>â<lpage>573</lpage> (<year>2012</year>) .<pub-id pub-id-type="pmid">23142591</pub-id></mixed-citation>
      </ref>
      <ref id="b18">
        <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>X. Q.</given-names></name>
<italic>et al.</italic>
<article-title>A novel heterozygous NR1H4 termination codon mutation in idiopathic infantile cholestasis</article-title>. <source>World J. Pediatr.</source>
<volume>8</volume>, <fpage>67</fpage>â<lpage>71</lpage> (<year>2012</year>) .<pub-id pub-id-type="pmid">21633855</pub-id></mixed-citation>
      </ref>
      <ref id="b19">
        <mixed-citation publication-type="journal"><name><surname>Pan</surname><given-names>X.</given-names></name>, <name><surname>Kelly</surname><given-names>S.</given-names></name>, <name><surname>Melin-Aldana</surname><given-names>H.</given-names></name>, <name><surname>Malladi</surname><given-names>P.</given-names></name> &amp; <name><surname>Whitington</surname><given-names>P. F.</given-names></name>
<article-title>Novel mechanism of fetal hepatocyte injury in congenital alloimmune hepatitis involves the terminal complement cascade</article-title>. <source>Hepatology.</source>
<volume>51</volume>, <fpage>2061</fpage>â<lpage>2068</lpage> (<year>2010</year>) .<pub-id pub-id-type="pmid">20512994</pub-id></mixed-citation>
      </ref>
      <ref id="b20">
        <mixed-citation publication-type="journal"><name><surname>Kir</surname><given-names>S.</given-names></name>, <name><surname>Kliewer</surname><given-names>S. A.</given-names></name> &amp; <name><surname>Mangelsdorf</surname><given-names>D. J.</given-names></name>
<article-title>Roles of FGF19 in liver metabolism</article-title>. <source>Cold Spring Harb. Symp. Quant. Biol.</source>
<volume>76</volume>, <fpage>139</fpage>â<lpage>144</lpage> (<year>2011</year>) .<pub-id pub-id-type="pmid">21813638</pub-id></mixed-citation>
      </ref>
      <ref id="b21">
        <mixed-citation publication-type="journal"><name><surname>Alisi</surname><given-names>A.</given-names></name>
<italic>et al.</italic>
<article-title>Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease</article-title>. <source>PLoS ONE</source>
<volume>8</volume>, <fpage>e67160</fpage> (<year>2013</year>) .<pub-id pub-id-type="pmid">23840612</pub-id></mixed-citation>
      </ref>
      <ref id="b22">
        <mixed-citation publication-type="journal"><name><surname>Freudenberg</surname><given-names>F.</given-names></name>, <name><surname>Gothe</surname><given-names>F.</given-names></name>, <name><surname>Beigel</surname><given-names>F.</given-names></name>, <name><surname>Rust</surname><given-names>C.</given-names></name> &amp; <name><surname>Koletzko</surname><given-names>S.</given-names></name>
<article-title>Serum 7-alpha-hydroxy-4-cholesten-3-one as a marker for bile acid loss in children</article-title>. <source>J. Pediatr.</source>
<volume>163</volume>, <fpage>1367</fpage>â<lpage>1371 e1361</lpage> (<year>2013</year>) .<pub-id pub-id-type="pmid">23968740</pub-id></mixed-citation>
      </ref>
      <ref id="b23">
        <mixed-citation publication-type="journal"><name><surname>Hori</surname><given-names>T.</given-names></name>
<italic>et al.</italic>
<article-title>Living-donor liver transplantation for progressive familial intrahepatic cholestasis</article-title>. <source>World. J. Surg.</source>
<volume>35</volume>, <fpage>393</fpage>â<lpage>402</lpage> (<year>2011</year>) .<pub-id pub-id-type="pmid">21125272</pub-id></mixed-citation>
      </ref>
      <ref id="b24">
        <mixed-citation publication-type="journal"><name><surname>Miyagawa-Hayashino</surname><given-names>A.</given-names></name>
<italic>et al.</italic>
<article-title>Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation</article-title>. <source>Liver Transpl.</source>
<volume>15</volume>, <fpage>610</fpage>â<lpage>618</lpage> (<year>2009</year>) .<pub-id pub-id-type="pmid">19479804</pub-id></mixed-citation>
      </ref>
      <ref id="b25">
        <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>F.</given-names></name>
<italic>et al.</italic>
<article-title>Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity</article-title>. <source>Gastroenterology</source>
<volume>126</volume>, <fpage>756</fpage>â<lpage>764</lpage> (<year>2004</year>) .<pub-id pub-id-type="pmid">14988830</pub-id></mixed-citation>
      </ref>
      <ref id="b26">
        <mixed-citation publication-type="journal"><name><surname>Zhan</surname><given-names>L.</given-names></name>
<italic>et al.</italic>
<article-title>Genome-wide binding and transcriptome analysis of human farnesoid X receptor in primary human hepatocytes</article-title>. <source>PLoS ONE</source>
<volume>9</volume>, <fpage>e105930</fpage> (<year>2014</year>) .<pub-id pub-id-type="pmid">25198545</pub-id></mixed-citation>
      </ref>
      <ref id="b27">
        <mixed-citation publication-type="journal"><name><surname>Anisfeld</surname><given-names>A. M.</given-names></name>
<italic>et al.</italic>
<article-title>Activation of the nuclear receptor FXR induces fibrinogen expression: a new role for bile acid signaling</article-title>. <source>J. Lipid Res.</source>
<volume>46</volume>, <fpage>458</fpage>â<lpage>468</lpage> (<year>2005</year>) .<pub-id pub-id-type="pmid">15604525</pub-id></mixed-citation>
      </ref>
      <ref id="b28">
        <mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>A.</given-names></name>
<italic>et al.</italic>
<article-title>Human kininogen gene is transactivated by the farnesoid X receptor</article-title>. <source>J. Biol. Chem.</source>
<volume>278</volume>, <fpage>28765</fpage>â<lpage>28770</lpage> (<year>2003</year>) .<pub-id pub-id-type="pmid">12761213</pub-id></mixed-citation>
      </ref>
      <ref id="b29">
        <mixed-citation publication-type="journal"><name><surname>Ananthanarayanan</surname><given-names>M.</given-names></name>, <name><surname>Balasubramanian</surname><given-names>N.</given-names></name>, <name><surname>Makishima</surname><given-names>M.</given-names></name>, <name><surname>Mangelsdorf</surname><given-names>D. J.</given-names></name> &amp; <name><surname>Suchy</surname><given-names>F. J.</given-names></name>
<article-title>Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor</article-title>. <source>J. Biol. Chem.</source>
<volume>276</volume>, <fpage>28857</fpage>â<lpage>28865</lpage> (<year>2001</year>) .<pub-id pub-id-type="pmid">11387316</pub-id></mixed-citation>
      </ref>
      <ref id="b30">
        <mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>L.</given-names></name>
<italic>et al.</italic>
<article-title>Farnesoid X receptor activates transcription of the phospholipid pump MDR3</article-title>. <source>J. Biol. Chem.</source>
<volume>278</volume>, <fpage>51085</fpage>â<lpage>51090</lpage> (<year>2003</year>) .<pub-id pub-id-type="pmid">14527955</pub-id></mixed-citation>
      </ref>
      <ref id="b31">
        <mixed-citation publication-type="journal"><name><surname>Oelkers</surname><given-names>P.</given-names></name>, <name><surname>Kirby</surname><given-names>L. C.</given-names></name>, <name><surname>Heubi</surname><given-names>J. E.</given-names></name> &amp; <name><surname>Dawson</surname><given-names>P. A.</given-names></name>
<article-title>Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2)</article-title>. <source>J. Clin. Invest.</source>
<volume>99</volume>, <fpage>1880</fpage>â<lpage>1887</lpage> (<year>1997</year>) .<pub-id pub-id-type="pmid">9109432</pub-id></mixed-citation>
      </ref>
      <ref id="b32">
        <mixed-citation publication-type="journal"><name><surname>Kubitz</surname><given-names>R.</given-names></name>, <name><surname>Droge</surname><given-names>C.</given-names></name>, <name><surname>Stindt</surname><given-names>J.</given-names></name>, <name><surname>Weissenberger</surname><given-names>K.</given-names></name> &amp; <name><surname>Haussinger</surname><given-names>D.</given-names></name>
<article-title>The bile salt export pump (BSEP) in health and disease</article-title>. <source>Clin. Res. Hepatol. Gastroenterol.</source>
<volume>36</volume>, <fpage>536</fpage>â<lpage>553</lpage> (<year>2012</year>) .<pub-id pub-id-type="pmid">22795478</pub-id></mixed-citation>
      </ref>
      <ref id="b33">
        <mixed-citation publication-type="journal"><name><surname>Magnusson</surname><given-names>M.</given-names></name>
<italic>et al.</italic>
<article-title>Bile acids and coagulation factors: paradoxical association in children with chronic liver disease</article-title>. <source>Eur. J. Gastroenterol. Hepatol.</source>
<volume>25</volume>, <fpage>152</fpage>â<lpage>158</lpage> (<year>2013</year>) .<pub-id pub-id-type="pmid">23075699</pub-id></mixed-citation>
      </ref>
      <ref id="b34">
        <mixed-citation publication-type="journal"><name><surname>Davit-Spraul</surname><given-names>A.</given-names></name>
<italic>et al.</italic>
<article-title>ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history</article-title>. <source>Hepatology.</source>
<volume>51</volume>, <fpage>1645</fpage>â<lpage>1655</lpage> (<year>2010</year>) .<pub-id pub-id-type="pmid">20232290</pub-id></mixed-citation>
      </ref>
      <ref id="b35">
        <mixed-citation publication-type="journal"><name><surname>Sinal</surname><given-names>C. J.</given-names></name>
<italic>et al.</italic>
<article-title>Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis</article-title>. <source>Cell</source>
<volume>102</volume>, <fpage>731</fpage>â<lpage>744</lpage> (<year>2000</year>) .<pub-id pub-id-type="pmid">11030617</pub-id></mixed-citation>
      </ref>
      <ref id="b36">
        <mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>G. L.</given-names></name>
<italic>et al.</italic>
<article-title>Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity</article-title>. <source>J. Biol. Chem.</source>
<volume>278</volume>, <fpage>45062</fpage>â<lpage>45071</lpage> (<year>2003</year>) .<pub-id pub-id-type="pmid">12923173</pub-id></mixed-citation>
      </ref>
      <ref id="b37">
        <mixed-citation publication-type="journal"><name><surname>Otte</surname><given-names>K.</given-names></name>
<italic>et al.</italic>
<article-title>Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol</article-title>. <source>Mol. Cell. Biol.</source>
<volume>23</volume>, <fpage>864</fpage>â<lpage>872</lpage> (<year>2003</year>) .<pub-id pub-id-type="pmid">12529392</pub-id></mixed-citation>
      </ref>
      <ref id="b38">
        <mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>Y.</given-names></name>
<italic>et al.</italic>
<article-title>Clinical whole-exome sequencing for the diagnosis of mendelian disorders</article-title>. <source>N. Engl. J. Med.</source>
<volume>369</volume>, <fpage>1502</fpage>â<lpage>1511</lpage> (<year>2013</year>) .<pub-id pub-id-type="pmid">24088041</pub-id></mixed-citation>
      </ref>
      <ref id="b39">
        <mixed-citation publication-type="journal"><name><surname>Larkin</surname><given-names>M. A.</given-names></name>
<italic>et al.</italic>
<article-title>Clustal W and Clustal X version 2.0</article-title>. <source>Bioinformatics</source>
<volume>23</volume>, <fpage>2947</fpage>â<lpage>2948</lpage> (<year>2007</year>) .<pub-id pub-id-type="pmid">17846036</pub-id></mixed-citation>
      </ref>
      <ref id="b40">
        <mixed-citation publication-type="journal"><name><surname>Kallberg</surname><given-names>M.</given-names></name>
<italic>et al.</italic>
<article-title>Template-based protein structure modeling using the RaptorX web server</article-title>. <source>Nat. Protoc.</source>
<volume>7</volume>, <fpage>1511</fpage>â<lpage>1522</lpage> (<year>2012</year>) .<pub-id pub-id-type="pmid">22814390</pub-id></mixed-citation>
      </ref>
      <ref id="b41">
        <mixed-citation publication-type="journal"><name><surname>Devarakonda</surname><given-names>S.</given-names></name>, <name><surname>Harp</surname><given-names>J. M.</given-names></name>, <name><surname>Kim</surname><given-names>Y.</given-names></name>, <name><surname>Ozyhar</surname><given-names>A.</given-names></name> &amp; <name><surname>Rastinejad</surname><given-names>F.</given-names></name>
<article-title>Structure of the heterodimeric ecdysone receptor DNA-binding complex</article-title>. <source>EMBO J.</source>
<volume>22</volume>, <fpage>5827</fpage>â<lpage>5840</lpage> (<year>2003</year>) .<pub-id pub-id-type="pmid">14592980</pub-id></mixed-citation>
      </ref>
      <ref id="b42">
        <mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>K.</given-names></name>
<italic>et al.</italic>
<article-title>Circadian dysregulation disrupts bile acid homeostasis</article-title>. <source>PLoS ONE</source>
<volume>4</volume>, <fpage>e6843</fpage> (<year>2009</year>) .<pub-id pub-id-type="pmid">19718444</pub-id></mixed-citation>
      </ref>
      <ref id="b43">
        <mixed-citation publication-type="journal"><name><surname>Camilleri</surname><given-names>M.</given-names></name>
<italic>et al.</italic>
<article-title>Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry</article-title>. <source>Neurogastroenterol. Motil.</source>
<volume>21</volume>, <fpage>734</fpage>â<lpage>e743</lpage> (<year>2009</year>) .<pub-id pub-id-type="pmid">19368662</pub-id></mixed-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="conflict">
        <p>B.L.S. is a consultant to Bristol Myers Squibb and Vertex Pharmaceuticals and has received investigator initiated support from Hyperion Therapeutics in the form of drug only for treatment of Byler's Disease. All other authors declare no competing financial interests.</p>
      </fn>
    </fn-group>
  </back>
  <floats-group>
    <fig id="f1">
      <label>Figure 1</label>
      <caption>
        <title>Histological and immunohistochemical findings in <italic>1HR1H4</italic> mutant livers.</title>
        <p>Expression of BSEP, MDR3 and FXR in liver (diaminobenzidine chromogen and hematoxylin counterstain) in patients with <italic>NR1H4</italic>-related cholestasis; normal controls in insets. Hematoxylin/eosin views for orientation. Original magnification, all images, Ã 200. BSEP and FXR are absent in all four patients when compared with positive control (inset). MDR3 is present in all four patients although reduced in patients 2 and 4. H&amp;E, hematoxylin and eosin.</p>
      </caption>
      <graphic xlink:href="ncomms10713-f1"/>
    </fig>
    <fig id="f2">
      <label>Figure 2</label>
      <caption>
        <title><italic>NR1H4</italic> mutations.</title>
        <p>(<bold>a</bold>) Sanger sequencing of the homozygous variant c.526C&gt;T (p.R176*) in patients 1 and 2 of family 1. Both parents are heterozygous carriers. (<bold>b</bold>) Sequence of the homozygous variant c.419_420insAAA (p.Tyr139_Asn140insLys) in patients 3 and 4 of family 2. The mother carries a heterozygous change. (<bold>c</bold>) Breakpoint junction mapping in family 2. PCR and Sanger sequencing confirmed a 31.7âkb deletion that spans the first two coding exons of all <italic>NR1H4</italic> isoforms. The deletion region is marked with a filled box. (<bold>d</bold>) All family 2 members except the mother carry this deletion. PCR was performed using forward and reverse primers indicated with arrow heads in <bold>d</bold>. Primer pair F1/R1b fails to amplify at the wild-type locus because the distance between them exceeds the limit of PCR reaction. Primer pair F1/R1 serves as control. NTC, no template control.</p>
      </caption>
      <graphic xlink:href="ncomms10713-f2"/>
    </fig>
    <fig id="f3">
      <label>Figure 3</label>
      <caption>
        <title>FXR Lys insertion mutation abrogates consensus IR-1 FXR binding and transactivation.</title>
        <p>(<bold>a</bold>) The highly conserved zinc-finger domain of the human FXR protein. The residue of nonsense mutation found in family 1 is indicated with a green arrow. The location of the in-frame Lys 140 insertion found in family 2 is indicated with a red arrow. âZn' stands for zinc ions. Cysteine residues that directly interact with zinc ions are in red. (<bold>b</bold>) Comparison of predicted structures of DBD. Predicted structures of wild-type FXR and FXR mutant with in-frame insertion based on the structure of EcR/RXR DBD in complex with IR-1 (PBD 1R0N). RXR is rendered in grey, EcR in orange, wild-type hFXR in cyan, hFXR mutant in purple and zinc ions are in green. The inserted lysine residue is in red with side chain shown. (<bold>c</bold>) Electrophoretic mobility-shift assay performed with a consensus FXRE or the FXR-binding region in mouse <italic>SHP</italic> promoter and wild-type or Lys insertion mutant FXR and RXR as indicated. (<bold>d</bold>) Relative luciferase expression directed by a reporter containing three copies of a consensus in response to wild-type and mutant FXR proteins in the presence or absence of the synthetic FXR agonist GW4064. Repeated three times (*<italic>P</italic>, 0.01 by <italic>t</italic>-test, error bars s.d.). FXRE, FXR-binding element.</p>
      </caption>
      <graphic xlink:href="ncomms10713-f3"/>
    </fig>
    <table-wrap position="float" id="t1">
      <label>Table 1</label>
      <caption>
        <title>Summary of clinical and laboratory findings in individuals harbouring mutations in <italic>NR1H4</italic>.</title>
      </caption>
      <table frame="hsides" rules="groups" border="1">
        <colgroup>
          <col align="left"/>
          <col align="center"/>
          <col align="center"/>
          <col align="center"/>
          <col align="center"/>
        </colgroup>
        <thead valign="bottom">
          <tr>
            <th align="left" valign="top" charoff="50">Â </th>
            <th colspan="2" align="center" valign="top" charoff="50">
              <bold>Family 1</bold>
              <hr/>
            </th>
            <th colspan="2" align="center" valign="top" charoff="50">
              <bold>Family 2</bold>
              <hr/>
            </th>
          </tr>
          <tr>
            <th align="left" valign="top" charoff="50">Â </th>
            <th align="center" valign="top" charoff="50">
              <bold>Patient 1</bold>
            </th>
            <th align="center" valign="top" charoff="50">
              <bold>Patient 2</bold>
            </th>
            <th align="center" valign="top" charoff="50">
              <bold>Patient 3</bold>
            </th>
            <th align="center" valign="top" charoff="50">
              <bold>Patient 4</bold>
            </th>
          </tr>
        </thead>
        <tbody valign="top">
          <tr>
            <td align="left" valign="top" charoff="50">Sex</td>
            <td align="center" valign="top" charoff="50">Female</td>
            <td align="center" valign="top" charoff="50">Male</td>
            <td align="center" valign="top" charoff="50">Female</td>
            <td align="center" valign="top" charoff="50">Male</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">Age at onset</td>
            <td align="center" valign="top" charoff="50">2 Weeks</td>
            <td align="center" valign="top" charoff="50">2 Weeks</td>
            <td align="center" valign="top" charoff="50">6 Weeks</td>
            <td align="center" valign="top" charoff="50">Birth</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">Age at initial evaluation</td>
            <td align="center" valign="top" charoff="50">20 Months</td>
            <td align="center" valign="top" charoff="50">7 Weeks</td>
            <td align="center" valign="top" charoff="50">6 Weeks</td>
            <td align="center" valign="top" charoff="50">Birth</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">Age at liver transplant</td>
            <td align="center" valign="top" charoff="50">22 Months</td>
            <td align="center" valign="top" charoff="50">4.4 Months</td>
            <td align="center" valign="top" charoff="50">NA</td>
            <td align="center" valign="top" charoff="50">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">Age at last evaluation</td>
            <td align="center" valign="top" charoff="50">10 Years</td>
            <td align="center" valign="top" charoff="50">15 Months</td>
            <td align="center" valign="top" charoff="50">Died at 8 months</td>
            <td align="center" valign="top" charoff="50">Died at 5 weeks</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">Symptoms</td>
            <td align="center" valign="top" charoff="50">Jaundice, FTT</td>
            <td align="center" valign="top" charoff="50">Jaundice, FTT</td>
            <td align="center" valign="top" charoff="50">Jaundice</td>
            <td align="center" valign="top" charoff="50">Hydrops, IVH</td>
          </tr>
        </tbody>
      </table>
      <table frame="hsides" rules="groups" border="1">
        <colgroup>
          <col align="left"/>
          <col align="center"/>
          <col align="center"/>
          <col align="center"/>
          <col align="center"/>
          <col align="center"/>
          <col align="center"/>
          <col align="center"/>
        </colgroup>
        <thead valign="bottom">
          <tr>
            <th align="left" valign="top" charoff="50">
              <bold>Liver biochemistry</bold>
            </th>
            <th align="center" valign="top" charoff="50">
              <bold>Initial evaluation</bold>
            </th>
            <th align="center" valign="top" charoff="50">
              <bold>Before OLT</bold>
            </th>
            <th align="center" valign="top" charoff="50">
              <bold>Initial evaluation</bold>
            </th>
            <th align="center" valign="top" charoff="50">
              <bold>Before OLT</bold>
            </th>
            <th align="center" valign="top" charoff="50">
              <bold>Initial evaluation</bold>
            </th>
            <th align="center" valign="top" charoff="50">
              <bold>Before death</bold>
            </th>
            <th align="center" valign="top" charoff="50">
              <bold>Birth to death</bold>
            </th>
          </tr>
        </thead>
        <tbody valign="top">
          <tr>
            <td align="left" valign="top" charoff="50">Direct bilirubin (nl &lt;0.4âmgâdl<sup>â1</sup>)</td>
            <td align="center" valign="top" charoff="50">11.5</td>
            <td align="center" valign="top" charoff="50">14.1</td>
            <td align="center" valign="top" charoff="50">11.8</td>
            <td align="center" valign="top" charoff="50">16.5</td>
            <td align="center" valign="top" charoff="50">9.2</td>
            <td align="center" valign="top" charoff="50">15.7</td>
            <td align="center" valign="top" charoff="50">0.2â13.5</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">AST (nl &lt;80 Uâl<sup>â1</sup>)</td>
            <td align="center" valign="top" charoff="50">231</td>
            <td align="center" valign="top" charoff="50">182</td>
            <td align="center" valign="top" charoff="50">392</td>
            <td align="center" valign="top" charoff="50">316</td>
            <td align="center" valign="top" charoff="50">293</td>
            <td align="center" valign="top" charoff="50">116</td>
            <td align="center" valign="top" charoff="50">83â341</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">ALT (nl &lt;80 Uâl<sup>â1</sup>)</td>
            <td align="center" valign="top" charoff="50">138</td>
            <td align="center" valign="top" charoff="50">90</td>
            <td align="center" valign="top" charoff="50">219</td>
            <td align="center" valign="top" charoff="50">132</td>
            <td align="center" valign="top" charoff="50">153</td>
            <td align="center" valign="top" charoff="50">62</td>
            <td align="center" valign="top" charoff="50">51â548</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">GGT (nl &lt;2 years &lt;100âUâl<sup>â1</sup>; &gt;2 years &lt;60âUâl<sup>â1</sup>)</td>
            <td align="center" valign="top" charoff="50">53</td>
            <td align="center" valign="top" charoff="50">41</td>
            <td align="center" valign="top" charoff="50">45</td>
            <td align="center" valign="top" charoff="50">44</td>
            <td align="center" valign="top" charoff="50">59</td>
            <td align="center" valign="top" charoff="50">38</td>
            <td align="center" valign="top" charoff="50">(107<xref ref-type="fn" rid="t1-fn3">*</xref>)</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">AFP (nl 8â468ângâml<sup>â1</sup>)</td>
            <td align="center" valign="top" charoff="50">716</td>
            <td align="center" valign="top" charoff="50">NM</td>
            <td align="center" valign="top" charoff="50">146,000</td>
            <td align="center" valign="top" charoff="50">400,000</td>
            <td align="center" valign="top" charoff="50">NM</td>
            <td align="center" valign="top" charoff="50">139,000</td>
            <td align="center" valign="top" charoff="50">NM</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">Â </td>
            <td align="center" valign="top" charoff="50">Â </td>
            <td align="center" valign="top" charoff="50">Â </td>
            <td align="center" valign="top" charoff="50">Â </td>
            <td align="center" valign="top" charoff="50">Â </td>
            <td align="center" valign="top" charoff="50">Â </td>
            <td align="center" valign="top" charoff="50">Â </td>
            <td align="center" valign="top" charoff="50">Â </td>
          </tr>
          <tr>
            <td colspan="8" align="center" valign="top" charoff="50">
              <italic>Coagulation parameters</italic>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">âPT (nl 10.3â13.4âs)</td>
            <td align="center" valign="top" charoff="50">23.9</td>
            <td align="center" valign="top" charoff="50">26</td>
            <td align="center" valign="top" charoff="50">21.3</td>
            <td align="center" valign="top" charoff="50">28.3</td>
            <td align="center" valign="top" charoff="50">17.4</td>
            <td align="center" valign="top" charoff="50">57.4</td>
            <td align="center" valign="top" charoff="50">
              <xref ref-type="fn" rid="t1-fn4">â </xref>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">âINR (nl 0.9â1.1)</td>
            <td align="center" valign="top" charoff="50">2.0</td>
            <td align="center" valign="top" charoff="50">2.2</td>
            <td align="center" valign="top" charoff="50">2.0</td>
            <td align="center" valign="top" charoff="50">2.8</td>
            <td align="center" valign="top" charoff="50">1.4</td>
            <td align="center" valign="top" charoff="50">7.4</td>
            <td align="char" valign="top" char="." charoff="50">2.05<xref ref-type="fn" rid="t1-fn4">â </xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">âFactor V assay (79â127%)</td>
            <td align="center" valign="top" charoff="50">31</td>
            <td align="center" valign="top" charoff="50">NM</td>
            <td align="center" valign="top" charoff="50">NM</td>
            <td align="center" valign="top" charoff="50">NM</td>
            <td align="center" valign="top" charoff="50">45</td>
            <td align="center" valign="top" charoff="50">NM</td>
            <td align="center" valign="top" charoff="50">NM</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">âFactor VII assay (51â116%)</td>
            <td align="center" valign="top" charoff="50">14</td>
            <td align="center" valign="top" charoff="50">NM</td>
            <td align="center" valign="top" charoff="50">NM</td>
            <td align="center" valign="top" charoff="50">NM</td>
            <td align="center" valign="top" charoff="50">32</td>
            <td align="center" valign="top" charoff="50">NM</td>
            <td align="center" valign="top" charoff="50">NM</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="t1-fn1">
          <p>AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FTT, failure to thrive; GGT, gamma-glutamyl transferase activity; INR, international normalized ratio; IVH, intraventricular haemorrhage; NM, not measured; NA, not applicable; nl, normal; OLT, orthotopic liver transplant; PT, prothrombin time.</p>
        </fn>
        <fn id="t1-fn2">
          <p>Patients 1 and 2 were from consanguineous parents, while patients 3 and 4 were not from consanguineous parents.</p>
        </fn>
        <fn id="t1-fn3">
          <p><sup>*</sup>5-day-old sampleânormal range for the GGT assay for patient 4 was 25â148âUâl<sup>â1</sup>.</p>
        </fn>
        <fn id="t1-fn4">
          <p><sup>â </sup>The values obtained were not representative because of transfusions required for volume/losses and blood pressure support.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap position="float" id="t2">
      <label>Table 2</label>
      <caption>
        <title>Relevant genetic findings in patients harbouring mutations in <italic>NR1H4</italic>.</title>
      </caption>
      <table frame="hsides" rules="groups" border="1">
        <colgroup>
          <col align="left"/>
          <col align="left"/>
          <col align="left"/>
          <col align="left"/>
          <col align="left"/>
        </colgroup>
        <thead valign="bottom">
          <tr>
            <th align="left" valign="top" charoff="50">Â </th>
            <th colspan="2" align="center" valign="top" charoff="50">
              <bold>Family 1</bold>
              <hr/>
            </th>
            <th colspan="2" align="center" valign="top" charoff="50">
              <bold>Family 2</bold>
              <hr/>
            </th>
          </tr>
          <tr>
            <th align="left" valign="top" charoff="50">Â </th>
            <th align="left" valign="top" charoff="50">
              <bold>Patient 1</bold>
            </th>
            <th align="left" valign="top" charoff="50">
              <bold>Patient 2</bold>
            </th>
            <th align="left" valign="top" charoff="50">
              <bold>Patient 3</bold>
            </th>
            <th align="left" valign="top" charoff="50">
              <bold>Patient 4</bold>
            </th>
          </tr>
        </thead>
        <tbody valign="top">
          <tr>
            <td colspan="5" align="left" valign="top" charoff="50">
              <italic>Genetics</italic>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50"><italic>âNRIH4</italic> first allele</td>
            <td align="left" valign="top" charoff="50">c.526C&gt;T p.Arg176*</td>
            <td align="left" valign="top" charoff="50">c.526C&gt;T p.Arg176*</td>
            <td align="left" valign="top" charoff="50">c.419_420insAAA (p.Tyr139_Asn140insLys)</td>
            <td align="left" valign="top" charoff="50">c.419_420insAAA (p.Tyr139_Asn140insLys)</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50"><italic>âNRIH4</italic> second allele</td>
            <td align="left" valign="top" charoff="50">c.526C&gt;T p.Arg176*</td>
            <td align="left" valign="top" charoff="50">c.526C&gt;T p.Arg176*</td>
            <td align="left" valign="top" charoff="50">31.7âkb deletion</td>
            <td align="left" valign="top" charoff="50">31.7âkb deletion</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>âABCB11</italic>
            </td>
            <td align="left" valign="top" charoff="50">None found</td>
            <td align="left" valign="top" charoff="50">None found</td>
            <td align="left" valign="top" charoff="50">Heterozygous c.1331T&gt;C p.V444A</td>
            <td align="left" valign="top" charoff="50">Homozygous c.1331T&gt;C p.V444A</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="t3">
      <label>Table 3</label>
      <caption>
        <title>Primer sets for real-time PCR analysis.</title>
      </caption>
      <table frame="hsides" rules="groups" border="1">
        <colgroup>
          <col align="left"/>
          <col align="center"/>
          <col align="center"/>
        </colgroup>
        <thead valign="bottom">
          <tr>
            <th align="left" valign="top" charoff="50">
              <bold>Gene</bold>
            </th>
            <th align="center" valign="top" charoff="50">
              <bold>Forward</bold>
            </th>
            <th align="center" valign="top" charoff="50">
              <bold>Reverse</bold>
            </th>
          </tr>
        </thead>
        <tbody valign="top">
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>GAPDH</italic>
            </td>
            <td align="center" valign="top" charoff="50">5'-CCAGCAAGAGCACAAGAGGA-3'</td>
            <td align="center" valign="top" charoff="50">5'-GAGATTCAGTGTGGTGGGGG-3'</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>FXR</italic>
            </td>
            <td align="center" valign="top" charoff="50">5'-GCTTTGCTGAAAGGGTCTGC-3'</td>
            <td align="center" valign="top" charoff="50">5'-CAGAATGCCCAGACGGAAGT-3'</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>SHP</italic>
            </td>
            <td align="center" valign="top" charoff="50">5'-TCAAGTCCATTCCGACCAGC-3'</td>
            <td align="center" valign="top" charoff="50">5'-AAGAAGGCCAGCGATGTCAA-3'</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>FGF19</italic>
            </td>
            <td align="center" valign="top" charoff="50">5'-AGATCAAGGCAGTCGCTCTG-3'</td>
            <td align="center" valign="top" charoff="50">5'-CGGATCTCCTCCTCGAAAGC-3'</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>BSEP</italic>
            </td>
            <td align="center" valign="top" charoff="50">5'-GAGCCTGGTCATCTTGTGCT-3'</td>
            <td align="center" valign="top" charoff="50">5'-TCTCCAGGGCCTGCTTATCT-3'</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>FGA</italic>
            </td>
            <td align="center" valign="top" charoff="50">5'-CTGCCTGGTCCTAAGTGTGG-3'</td>
            <td align="center" valign="top" charoff="50">5'-GCAGAAGGGCCAGTCTGAAT-3'</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>FGB</italic>
            </td>
            <td align="center" valign="top" charoff="50">5'-ACCATGGAAAAGCCACCACT-3'</td>
            <td align="center" valign="top" charoff="50">5'-CGTTTCTATGGGCAACAGGC-3'</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>FGG</italic>
            </td>
            <td align="center" valign="top" charoff="50">5'-CACACAGTCTGCCATCCCATA-3'</td>
            <td align="center" valign="top" charoff="50">5'-ACTTGTCAGCTTCAGGTCCC-3'</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>F3</italic>
            </td>
            <td align="center" valign="top" charoff="50">5'-ACTCCCCAGAGTTCACACCT-3'</td>
            <td align="center" valign="top" charoff="50">5'-TCCCGGAGGCTTAGGAAAGT-3'</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>F12</italic>
            </td>
            <td align="center" valign="top" charoff="50">5'-AGCTGAAGAGCACACAGTCG-3'</td>
            <td align="center" valign="top" charoff="50">5'-CGGCCCTTGTGGGTACATTT-3'</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>F13b</italic>
            </td>
            <td align="center" valign="top" charoff="50">5'-GAATGCAATGTGACAGAGGGC-3'</td>
            <td align="center" valign="top" charoff="50">5'-TGACTCCTCTTTCTGCCATTCA-3'</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>